升麻总苷抗肿瘤活性及其对肿瘤细胞周期的影响*

摘要

Objective To investigate the anti-tumor activity of total glycoside of Cimicifuga foetida L.(TGC) and its mechanism. Methods The growth inhibitory effect of TGC on human hepatoma cell line HepG2 was observed by using assay(MTT);In vivo anti-tumor activity of TGC were evaluated in transplant hepatoma H22 model and human hepatocellular carcinoma Bel-7402 xenograft nude mice model;Cell cycle distribution was assayed by flow cytometry. Results TGC could markedly inhibit the growth of HepG2 (IC50=76.16 ±2.94 mg·L-1). Compared with the solvent group,TGC showed a significant inhibitory effect on H22 and Bel-7402 at a dose of 0.8 g·kg-1. Furthermore,TGC could arrest HepG2 at G2/M phase at a concentration of 50 mg·L-1 in a time-dependent manner. Conclusion TGC had significant anti-tumor effects both in vivo and in vitro,which might be associated with the arresting of the tumor cell cycle at G2/M phase.%目的研究升麻总苷提取物（Total Glycoside of Cimicifuga foetida，TGC）的体内、外抗肿瘤活性及其对人肿瘤细胞周期分布的影响。方法 MTT法检测TGC对人肿瘤细胞株的增殖抑制活性；体内实验观察TGC对小鼠肝癌H22移植瘤和人肝癌裸小鼠异种移植瘤Bel-7402的抑制作用；荧光染色法和流式细胞仪检测其对肿瘤细胞周期的影响。结果 TGC可明显抑制人肝癌HepG2细胞的增殖，其IC50值为（76.16±2.94） mg·L-1；TGC 0.8 g·kg-1剂量可明显抑制小鼠肝癌H22和人肝癌Bel-7402裸小鼠移植瘤的生长；TGC 50 mg·L-1可明显诱导人肝癌HepG2细胞阻滞于G2/M 期，呈现出一定的时-效关系。结论 TGC具有明显的体内、外抗肿瘤作用，其活性可能与阻滞肿瘤细胞周期有关。